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Abstract 
Background 
Soft tissue sarcomas (STS) are a diverse group of malignancies that remain a diagnostic and 
therapeutic challenge.  Relatively few reliable cell lines currently exist.  Rapidly-developing technology 
for genomic profiling with emerging insights into candidate functional (driver) aberrations raises the 
need for more models for in vitro functional validation of molecular targets. 
Methods 
Primary cell culture was performed on STS tumours utilising a differential attachment approach. Cell 
lines were characterised by morphology, immunocytochemistry, proliferation assays, Short Tandem 
Repeat (STR) and Microarray-based Genomic copy number profiling. 
Results 
Of 47 STS cases of various subtypes, half formed adherent monolayers.  Seven formed self-
immortalised cell lines, including 3 undifferentiated pleomorphic sarcomas, 2 dedifferentiated 
liposarcomas (one of which had received radiotherapy), a leiomyosarcoma and a myxofibrosarcoma.  
Two morphologically-distinct yet genetically-identical variants were established in separate cultures 
for the latter two tumours.  All cell lines demonstrated genomic and phenotypic features that not only 
confirm their malignant characteristics, but confirm retention of DNA copy number aberrations present 
in their parent tumours that likely include drivers.   
Conclusion 
These primary cell lines are much-needed additions to the number of reliable cell lines of STS with 
complex genomics available for initial functional validation of candidate molecular targets. 
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Introduction 
Soft tissue sarcomas (STS) are a diverse group of malignant tumours that arise in mesenchymal 
tissues and represent around 1% of adult human malignancies.  Comprising over 50 clinico-
biologic/molecular subtypes, the majority of STS subtypes remain a significant diagnostic and 
treatment challenge (Fletcher et al, 2013; Italiano et al, 2016).  Only a small proportion (approximately 
20%) have known specific diagnostic markers such a gene mutations or chromosomal translocations 
and fewer still possess identified molecular therapeutic targets  (Fletcher et al, 2013; Taylor et al, 
2011).  The remainder are characterised by pervasive chromosomal instability evidenced by multiple 
seemingly random somatic DNA copy number aberrations.  Elucidation of as yet unknown patterns 
among these complex genomic abnormalities is believed to be the key to accurate diagnosis and 
identification of molecular therapeutic targets in these heterogenic tumours (Barretina et al, 2010; 
Taylor et al, 2011).     
Traditionally, the first step of therapeutic target validation for candidate driver genes or proteins 
utilises in vitro disease models (Taylor et al, 2011).  Recent improvements in the technology for 
genomic aberration mapping such as high resolution microarray-based comparative genomic 
hybridisation (array CGH) and next generation sequencing have led to an increased rate of candidate 
identification and therefore a growing need to establish a wider range of STS cell lines for functional 
testing (Barretina et al, 2010; Taylor et al, 2011).  In STS however, there is a limited number of in vitro 
disease models (tumour cell lines) available for functional testing and target validation.   Data from 
large-scale cancer cell line studies such as the Cancer Cell Line Encyclopaedia and Sanger Cancer 
Cell Line Project showed that less than 2% of the commercially available cell lines studied are derived 
from STS and the majority of these belong to the translocation-driven subgroup (Barretina et al, 2012; 
Forbes et al, 2011).   
There has been increasing recognition of the limitations of commercial cell lines as a disease model 
stemming from reports of poor correlation of the response in these cell lines with in vivo tumour 
behaviour (Cree et al, 2010; Kamb, 2010).  With cellular adaptation to artificial culture conditions, cell 
lines have been shown to grow more rapidly than parent tumour cells and acquire phenotypic 
changes that may alter their therapeutic response, such as dependence on growth factors in culture 
media or adherence to plastic (Kato et al, 2008; Pan et al, 2009).  Furthermore, heterogeneity of 
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tumour cell clones, which is characteristic of many cancers is lacking in cell lines in which single 
clones have been selected for and is widely believed to account for the poor correlation of preclinical 
and clinical data as the cell lines may not reflect resistant tumour cell clones or cancer ‘stem’ cells 
that are believed to be responsible for tumour recurrence and late therapeutic failure (Kamb, 2010). 
One widely accepted alternative to traditional established (or commercially available) cell lines is the 
use of cells cultured directly from tumours (primary cell cultures) as in vitro disease models.  This is 
however fraught with many problems (Luca et al, 2007).  Fresh tumour tissue has to be donated by 
patients and obtained during surgery with the associated ethical and logistic constraints.  When 
available, the behaviour of primary tumour cells in culture is generally unpredictable with a variable 
rate of successful establishment (Luca et al, 2007).   
This paper describes our experience of primary tissue culture of soft tissue sarcoma cells and the 
establishment and molecular characterization of self-immortalised primary cell lines, including 
morphologic variants derived from seven soft tissue sarcomas. 
Materials and Methods 
Ethics Statement 
National Research Ethics Committee approval was obtained for the collection and use of tumour 
tissue (Reference number 09/H1313/52).  Written informed consent was obtained from all patients 
prior to the tumour tissue collection, all tissue was stored according to the principles of the 
Declaration of Helsinki and used in compliance with the Human Tissue Act 2004.  
Tumour Samples 
Fresh tumour samples were obtained from 47 patients receiving surgical treatment for biopsy-
confirmed STS at Sheffield Teaching Hospitals.  Preoperative sarcoma diagnoses were confirmed by 
pathological assessment of the resected tumours which were classified according to WHO diagnostic 
categories (Fletcher et al, 2013) and reported according to Royal College of Pathologists guidelines 
(Fisher, 2014).  Within 30 minutes of resection, tumours were macroscopically sampled by 
specialised sarcoma pathologists and collected in sterile phosphate-buffered saline (PBS) with 
additional tumour samples snap-frozen and stored in liquid nitrogen or at -80ºC until DNA extraction.  
Normal tissue where available typically as part of a wide resection specimen,  was obtained from sites 
macroscopically distant from the tumour and snap-frozen in liquid nitrogen. . 
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Establishment of Primary Tumour Cell Cultures 
Tumour cell cultures were set up under sterile conditions within one hour of surgical resection by 
simple mechanical tissue dissociation using RPMI 1640 culture medium supplemented with penicillin 
(100U/ml), Streptomycin (100µg/ml), amphotericin B (5µg/ml), foetal calf serum (20% v/v) and D-
glucose (0.4% v/v).  Briefly, a small piece (around 10 × 10 × 5mm) of fresh tumour was placed in a 
sterile petri dish with a few drops pre-warmed (37oC) culture media and minced with a sterile scalpel 
until very fine.  Minced tumour was then suspended in warm media and centrifuged before transfer in 
fresh warm media to sterile 25mm2 tissue culture (T25) flasks and 5mm2 flat sided tubes (slopes) and 
placed in a 5% CO2 incubator at 37oC in 95% humidified air.  All cultures were inspected daily using a 
phase-contrast microscope and media changed as required. 
A modification of the differential attachment approach described by Nayak and colleagues (Nayak et 
al, 2000) was used and washes were set up when it appeared that some viable cells in early cultures 
remained unattached to culture flasks.  The media containing non-adherent cells was collected and 
replaced with fresh media, then centrifuged and the pellet re-suspended in fresh pre-warmed media 
and transferred into a new T25 flask for incubation. Adherent cell cultures were maintained by serial 
passage with gentle trypsinisation at confluence.  In case they were undergoing a crisis period, 
cultures in which the majority of cells appeared senescent were maintained for at leasta further  3 
months with daily visual inspection and the media changed as required. 
Cultures were given STS laboratory designations based on the chronological order and year in which 
they were established and passage numbers were indicated using a ‘p’ prefix.  For example, STS 
03/10 p2 refers to the second passage of cultures derived from the third tumour obtained in 2010.  
Cultures that were set up as washes were designated with a ‘w’ prefix to the passage number.  For 
example, cells from the second wash of an original T25 flask culture setup and currently in their third 
passage were designated were designated w2p3 while cells from a wash of an original slope set up at 
the same passage were designated wsp3.  Cells from original culture setup and washes were 
maintained separately with all relevant precautions to prevent cross-contamination.  In order to make 
them more recognisable, the nomenclature of cultures that formed stable cell lines was revised to 
reflect the STS subtype they represent and their city of origin (see below). 
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Proliferation Assay and Doubling Time  
Cells were seeded at a density of 2 x 103 in individual wells of a 96-well plate and the MTT ((4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) proliferation assay was performed as 
previously described (Canovas et al, 2008).  The ratio of absorbance in the test wells to control wells 
(containing 100µl DMSO only) was calculated as relative MTT activity and used as a surrogate for the 
number of viable cells remaining in culture.  Average relative MTT activity from four replicate wells 
was plotted against time and the exponential growth curve plotted and doubling time calculated using 
GraphPad Prism® software v6.0.   
Short tandem Repeat Profiling 
Short Tandem Repeat (STR) Profiling to establish unique genomic identities and exclude cross-
contamination of cell lines was performed using services provided by the University of Sheffield Core 
Genomic Facility.  Alleles for 10 human loci including THO1 D21S11 D5S818 D13S317 D7S820 
D16S539 CSFIPO AMEL vWA and TPOX were assessed and compared with large cell line STR 
profile databases using the standard match threshold of 80% (Capes-Davis et al, 2013) 
Microarray-based Comparative Genomic Hybridisation (Array CGH) 
Genomic DNA extraction and array CGH were performed using the Agilent® 180K platform as 
previously described (Salawu et al, 2012).  Control DNA was extracted from normal tissue obtained 
from the same patient where available.  Otherwise, pooled sex-matched genomic DNA (Promega®) 
was used.  Agilent® Genomic Workbench Software v6.0 was used for copy number data analysis and 
graphical representation on ideograms. 
Immunocytochemistry 
Cells were prepared for immunocytochemistry by culturing on sterile glass slides for 48 hours prior to 
fixing with ice cold acetone-methanol (1:1 mixture).  Fixed cells were then pre-treated with Triton 
(0.1% v/v) and H2O2 (3%) prior to immunostaining.  Primary antibodies for Cytokeratin, Vimentin, 
Smooth Muscle Actin (SMA) and CD117 (c-kit) were used (see supplementary data Table S1 for 
details).  The Vectastain® system appropriate for each primary antibody was then used according to 
manufacturers’ instructions for secondary antibody staining and detection.  Confirmation of staining 
pattern was performed by light microscopy at appropriate magnification.   
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Results 
Establishment of Primary Tumour Cell Cultures in various STS subtypes 
Forty-seven STS cases comprising 16 different subtypes were set up in culture (see Table 1 for 
details).  Failure to establish adherent cultures or early senescence within the first or second passage 
(p1 – p2) was observed in ten cases.  Later senescence occurred in about a third of cases and was 
generally observed at two points. The first was around the fifth passage (p4 - p7) and the second, 
after around ten passages (p9 – p12).   All cultures that continued beyond 12 passages went on to 
become stable self-immortalised cell lines that maintained reliably proliferative cultures for over three 
years with consistent and reliable proliferation rates.  In all but one of these cases (a 
leiomyosarcoma) that formed stable cell lines, the cells adapted to proliferative tissue culture quite 
rapidly (within days) and no significant crisis period was seen (discussed later).  Also of note was that 
, long term cultures leading to stable cell lines were derived not from the original culture setups but 
from washes in three seven tumours and in two of these cases, separate washes led to the 
establishment of morphologically variant cultures of the same tumours, lending support to the 
differential attachment approach that was used.  
Neoadjuvant local or systemic treatment is expected to adversely impact tissue culture outcomes.  It 
was interesting to note, however that both STS cases in which the patient had received neo-adjuvant 
chemotherapy were able to establish cells that were passaged up to ten times before subsequent 
senescence and one of four tumours that received neo-adjuvant radiotherapy resulted in a stable cell 
line (Table 1).  Undifferentiated pleomorphic sarcoma (UPS) was the STS subtype that had the most 
successful outcome with stable cell lines established in three out of seven cases.  Of the UPS 
cultures that did not result in a stable cell lines, two out of the four had received neoadjuvant 
treatment.   Well-differentiated liposarcoma, on the other hand was the STS subtype that had the 
poorest culture outcome overall with only one of the seven cases able to establish any cells in 
adherent culture and these subsequently underwent early senescence (Table 1).   
In order to minimise the effects of genomic drift and cultural adaptation in future experiments, cultured 
cells were frozen at -80oC and subsequently in liquid nitrogen every 3 - 4 passages, within the first 15 
passages. Table 2 summarises the nomenclature, clinical and cultural phenotypic characteristics of  
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the seven tumours that established long term primary cell cultures and which are the focus of the rest 
of this manuscript.  
Morphology and Culture Characteristics 
The majority of the STS primary cell lines were composed of cells that were morphologically 
homogenous (Figure 1A and 1B).  The exceptions were Shef-DDLPS 01, Shef-UPS 02 and Shef-
DDLPS 02  (Table 2).  Cells in the former two cultures were mostly spindle-shaped but showed 
significant variation in their size and shape (Figure 1C).  Neither showed distinct colony formation 
while in adherent culture.  Shef-DDLPS 02 cultures on the other hand were dimorphic with one clone 
of long, spindle-shaped cells that were more numerous and a second population of rounded, 
histiocyte-like cells with distinct nuclei.  Both cell populations tended to grow in tight colonies (Figure 
1D).   In common with Shef-DDLPS 02, Shef-LMS 01 and Shef-MFS 01 cultures were composed of 
two distinct morphologic cells populations (variants), but these were established as separate 
morphologically homogenous cultures.     
The first Shef-LMS 01 clone was established as a wash from an original slope setup following an 
approximately 8-week period of crisis and designated, ws variant.  These cells had a rounded 
histiocyte-like morphology in adherent culture and grew in distinct, tight colonies (Figure 1E).  A 
subsequent clone became established independently (after around 12 weeks of crisis) in the first 
wash of an original T25 flask set up and  designated the w1 variant.   They were slightly longer, spindle 
shaped cells that also formed tight colonies (Figure 1F).  Similarly, Shef-MFS 01 cells established in 
the initial and subsequent washes derived from the original T25 flask set up, designated w1 and w2 
respectively, showed distinct appearance in culture.  While the former comprised cells with a rounded, 
histiocyte-like morphology that grew in distinct colonies (Figure 1G), the w2 variant cells had a more 
polygonal morphology and formed less-distinct colonies (Figure 1H).   STR profiling of the 
morphologic variants in both tumours showed identical profiles that reassuringly, were significantly 
distinct from those of all the other cell lines in our laboratory and the examined databases (Table 3).  
Further details of the culture characteristics are shown in supplementary data (Figures S1 to S7). 
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STR profiling 
STR profiling of primary STS cell lines using 10 loci was used to establish cell line identity and 
exclude cross contamination.  Analysis confirmed unique genomic identities for cell lines derived from 
all seven cases and matched the identity for those cases with separate morphologically variant 
cultures (Table 3).  There was no evidence of significant relatedness with any other known cell lines 
or intra-laboratory cross-contamination.  Alleles for the AMEL locus were also concordant with the 
known gender of the patients from which all cell lines were derived, adding further confidence in the 
origin of these cell lines. 
Profiling was repeated after a further year in culture (30 – 40 passages) in five cases.  All retained 
overall unique profiles when checked against the cell line databases.  Minimal evidence of genomic 
drift with prolonged in vitro culture was observed with only single-locus loss of heterozygosity (LOH) 
noted in three cell lines despite their characteristic genomic instability (Table 3). 
Immunocytochemistry 
Immunocytochemistry for vimentin was positive in all seven primary STS cell lines, while cytokeratin 
was consistently negative in keeping with their mesenchymal origin (Table 2).  These results were 
also concordant with the immunophenotype at diagnosis of the corresponding tumour tissue of origin 
in all cases. The leiomyosarcoma cell line Shef-LMS 01 remained strongly positive for smooth muscle 
actin (SMA) and negative for c-KIT expression even after 61 passages, supporting its smooth muscle 
lineage of differentiation (not shown).  None of the other cell lines stained positive for c-kit or SMA, 
except Shef-DDLPS 02, a de-differentiated liposarcoma that stained weakly positive for SMA (Table 
2).   
Ploidy 
As expected in tumours known to possess complex karyotypes, metaphase chromosome spreads 
from all the STS cell lines examined showed significant aneuploidy with chromosome counts as high 
as 200 in some cases (see supplementary data Table S2). The highest chromosome counts were 
seen in Shef-LMS 01 and Shef-UPS 02 that had mean chromosome counts of around 120.  It is 
interesting to note that these cell lines also had the shortest doubling times (Table 2).  The lowest 
chromosome counts were seen in Shef-UPS 03 with a mean count of 58 chromosomes.   
The majority of the cell lines, including those with very homogenous cytomorphologic appearance on 
microscopy showed significant intratumour, heterogeneity with wide ranges of chromosome counts in 
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each metaphase spread.  The sole exception was Shef-UPS 01 showed a fairly consistent near-
triploid chromosome count (supplementary data Table S2).  Further characterisation using 
conventional cytogenetics was not performed in favour of molecular cytogenetic profiling as described 
below. 
DNA Copy Number Profiling 
Given the characteristic karyotypic complexity of these STS subtypes, our ability to demonstrate 
similarities in presumably random somatic copy number abnormalities (SCNA) across the genome 
serves as an important method of establishing how well a cell line represents its parent tumour.  
Whole genome copy number profile comparisons of paired DNA samples from each parent STS 
tumour and at least one of the corresponding primary tumour cell lines was therefore carried out using 
a high-resolution array CGH platform.  Control DNA was obtained from normal viscera such as kidney 
and uterus that were resected as part of surgical excision in Shef-DDLPS 01 and Shef-LMS 01, 
respectively.  In all other cases, pooled genomic DNA was used as control.  Identical control DNA 
samples were used for all parent tumour and corresponding cell line pairs that were compared. 
Analysis confirmed that all seven cell cultures analysed were related to their parent tumours. The 
greatest similarity across the whole genome was seen with Shef-DDLPS 02, Shef-UPS 01 and Shef-
UPS 02 (Figure 2).  While this was expected in the former two, where the cultured cell DNA used for 
comparison was extracted within the first five passages, that from Shef-UPS 02 which was performed 
after over 40 passages was rather interesting (Figure 2).  When examined at higher resolution, even 
the cell lines that showed the greatest dissimilarity across the whole genome retained striking 
similarities at certain genomic loci with very similar moving average log2ratio patterns and identical 
SCNA breakpoints.  Examples as shown in Figure 3 include the deletion on the short arm of 
chromosome 9 seen in Shef-LMS 01, the proximal 2q amplicon in Shef-UPS 03 and the 5p 
amplification of Shef-MFS 01.  Notably, two of these parent tumours were able to establish more than 
one morphologically-distinct cell type in long term culture, suggesting that and the dissimilarity in the 
SCNA profile comparisons may be a reflection of the inherent heterogeneity of the parent tumour 
DNA when compared with the clonal homogeneity of the corresponding cell culture. 
  
11 
 
Discussion 
Commercial cell lines are a widely used in vitro disease model for initial functional validation studies 
of molecular candidate drivers in spite of their recognised limitations.  This is because they are a 
readily available, endlessly replicating source of tumour material from which results obtained are 
usually reproducible  (Cree et al, 2010).  Many researchers however believe that successful bench to 
bedside translation of in vitro results is well worth the effort of obtaining primary cell cultures while 
others use results from primary cultures to augment those from the readily available commercial cell 
lines, instead of replacing them entirely (Cree et al, 2010).   
In this study, establishment of primary cell cultures was attempted with all fresh STS tissue collected 
with a success rate of over 70% confluent cultures and more than half the adherent monolayers able 
to undergo four passages or more (Table 1).  This rate is very comparable to previous studies which 
reported success rates of between 5 and 33% when cultures were attempted from primary solid 
tumours and slightly higher success rates from tumour metastases (Gazdar et al, 1998; McBain et al, 
1984; Nayak et al, 2000) or xenograft-derived cultures (Dangles-Marie et al, 2007; Kamiyama et al, 
2013).  Seven tumours (15% of cases) have established stable cell lines whose genomic and 
phenotypic characteristics were evaluated and compared to those of their corresponding parent 
tumours in order to confirm their suitability for functional validation studies.  Cells were frozen down at 
intervals at early passages to minimise culture-related genomic drift when cells are used in 
experiments.   
Among the fourteen cases that failed to establish adherent cultures, eight were well-differentiated or 
myxoid liposarcomas that had high fat and/or myxoid components relative to cell number, which is 
believed to have reduced the likelihood of adherent culture using the manual mechanical tissue 
dissociation applied in this study.  Simultaneous use of the explant method of culture establishment 
(Mitra et al, 2013) in some of these cases only yielded slow-growing, fibroblast-like cells that failed to 
reach confluence (data not shown).    
Application of the principle of differential attachment as described by Nayak and colleagues (Nayak et 
al, 2000) led to establishment of long term cultures in washes in  three cases (Shef-DDLPS 01, Shef-
LMS 01 and Shef-MFS 01) when cells adherent in the original culture setups became senescent.  In 
the latter two cases, it also led to the establishment of separate cultures of two morphologically 
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distinct variants each (Figure 1 and Table 2).   Since both cell populations in these cultures were 
exposed to otherwise identical culture conditions, it is most likely that the variants represent separate 
clones present within the parent tumour rather than differential adaptation to culture conditions.  
Similar observations have been made in multiple cases of primary breast carcinoma tissue culture 
(McBain et al, 1984).   
STR profiling which is the current recommended standard for cell line identification (American Type 
Culture Collection Standards Development Organization Workgroup, 2010) not only reliably confirmed 
identical profiles for the morphologic variants in Shef-LMS 01 and Shef-MFS 01, but established 
unique genomic identities for all the primary tumour cell lines reported in this study (Table 3).  LOH 
events were observed when STR profiling was repeated after around 40 subsequent cell passages, 
which likely represent genomic drift that would be expected in cells undergoing progressive in vitro 
culture (Capes-Davis et al, 2013).  The rate of genomic drift has been shown to be higher in cells that 
possess microsatellite instability (Masramon et al, 2006), a phenotype that has demonstrated in 
several studies of soft tissue and bone sarcomas, where it is believed to be due to their overall 
genomic instability and not necessarily due to the classical defects in mismatch repair as seen in 
other cancers (Monument et al, 2012).  While reassuring, the low frequency of LOH events seen in 
these cell lines after prolonged culture (Table 3) was therefore rather surprising.   
All the cell lines remained proliferative in culture for at least three years and had each been passaged 
at least 60 times.  Assessment of their doubling times showed proliferation rates that are comparable 
to those of well-known sarcoma cell lines such as SK-LMS1 and U2-OS as well as other tumour cell 
lines (McBain et al, 1984).  Similarly, clonal-plating efficiency of the primary UPS and LMS subtypes 
of these cell lines (data not shown) ranged between 25 and 50% comparing favourably with around 
30% efficiency reported for the SK-LMS1 cell line in our lab and by other investigators (Kappler et al, 
2004; Murphy et al, 2008).  These results reflect the cancer hall marks of increased proliferation and 
survival among these primary cell lines (Hanahan & Weinberg, 2011).   
Characterisation of primary cells cultures for use as models in target validation studies is essential 
due to the potential for fibroblast overgrowth in early cultures (Mitra et al, 2013) and cross 
contamination by other established cell lines in longer term cultures (Gillet et al, 2013).  Morphological 
characterisation may be unreliable because of the potential effects of an artificial in vitro 
microenvironment on tumour cell morphology.  In most cancers therefore, detection of diagnostic 
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biomarker expression by immunochemistry or flow cytometry are commonly used for characterisation.  
The common biomarkers of tumour cell lineage such as cytokeratin (CK), vimentin, smooth muscle 
actin (SMA), S100 and CD34, however have variable sensitivity and are not specific for many STS 
subtypes (Coindre, 2003; Fisher, 2011).  Immunochemistry for panels of these markers however 
remains relevant to diagnostic practice because when interpreted with the appropriate expertise and 
as an adjunct to histology, they are helpful for the exclusion of benign and non-mesenchymal tumours 
as well as suggest differentiation lineages in certain STS subtypes.  To this end, the 
immunochemistry results from this study provided support for a mesenchymal lineage for the 
established cell lines and were concordant with those of their parent tumours, suggesting that they 
represent those tumours at least to some extent (Table 2).  
All the STS subtypes from which cell lines were developed in this study are known to possess 
genomic instability and complex karyotypes (Fletcher et al, 2013; Taylor et al, 2011).  All seven cases 
showed highly abnormal chromosome numbers and in some cases, significant changes in 
chromosome numbers with increased time in culture that reflects inherent genomic instability that is 
part of the cancer cell phenotype (Hanahan & Weinberg, 2011).  Array CGH, a method that allows the 
mapping of the complex DNA copy number abnormalities across entire genomes and contributed 
significantly to the recent WHO classification of STS (Fletcher et al, 2013) was therefore used for 
definitive genomic characterisation of the tumour cell lines.  Importantly, it also permits the matching 
of unique and presumably random genomic aberrations that the cell lines and their parent tumours 
have in common. 
Genomic copy number profiles in all seven long-term cell cultures when compared with the 
corresponding parent tumours showed overall similarity in log ratio patterns (Figure 2).   A number of 
regions with differences in their SCNA pattern were noted.  In line with the clonal evolution model of 
cancer, the genomic instability that is inherent with these tumours combined with their rapid 
proliferation is expected to result in significant heterogeneity of tumour cell clones that may be under-
represented in the cell line (Anderson et al, 2011; Greaves & Maley, 2012).    This was likely the case 
in Shef-LMS 01 and Shef-MFS 01 where the genome profile of the parent tumour was compared with 
that of one of two confirmed clonal tumour cell variants in culture (Figure 2; supplementary data 
Figures S3 and S7).  Further, prolonged in vitro cell culture in addition to the aforementioned factors 
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is expected to result in the accumulation of genomic copy number or structural karyotypic aberrations, 
most of which are functionally neutral i.e. ‘passengers’  (Gillet et al, 2013; Greaves & Maley, 2012).   
Overall however, the genomic regions with dissimilar aberrations were few when compared to those 
regions that showed very similar SCNA patterns with near-identical breakpoints.  This was seen even 
after 40 passages in culture in the case of Shef-UPS 02 (Figures 2 and 3) and suggests that these 
cell lines are a suitable in vitro disease model as even large-scale studies evaluating the relevance of 
established cell lines in various cancers have shown that ‘driver’ genomic aberrations are nearly 
always retained in well-established commercial cell lines and vice versa despite evidence of genomic 
drift (Barretina et al, 2012; Beroukhim et al, 2010; Gazdar et al, 2010).  Moreover, early passages of 
all the cell lines in this study that presumably bear a closer genomic and phenotypic resemblance to 
the parent tumour have been banked and can be used for target validation studies. 
Among the seven tumours that established long term cultures, three were undifferentiated 
pleomorphic sarcomas, representing half of the cases that were obtained of this characteristically 
aggressive STS subtype (Fletcher et al, 2013).  The other STS subtypes that formed long term 
cultures were also of a high grade.   This suggests that overall, high grade and aggressive clinical 
course in STS may correlate with amenability to in vitro growth, as was observed in primary cultures 
of breast (Gazdar et al, 1998) and colorectal cancer tissue (McBain et al, 1984).  The three 
undifferentiated pleomorphic sarcoma cell lines notably demonstrate very different morphology, 
doubling time and chromosome numbers, which is not unexpected given that this diagnosis is largely 
one of exclusion (Fletcher et al, 2013) and likely includes a number of as yet undefined biologic 
tumour entities.   
Shef-DDLPS 02 was derived from a patient who received neo-adjuvant radiotherapy for 
dedifferentiated liposarcoma with partial response and the cell line probably represents a radio-
resistant clone of cells present within that tumour.   It is notable that array CGH analysis of this cell 
line (and its parent tumour) did not show 12q amplification (typically involving the MDM2 and/or CDK4 
genes) that is frequently seen well- and del-differentiated liposarcomas and was present in Shef-
DDLPS 01 (Figure 2) and four other liposarcoma cases in this study (Table 1; array CGH data not 
shown).  This is in keeping with data from large scale genomic studies of STS such as the sarcoma 
genome project showed that up to 10% of DDLPS have neither CDK4 nor MDM2 amplification 
(Barretina et al, 2010).  Review of the tumour histology confirmed a biphasic appearance with an area 
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of atypical adipocytic differentiation and other areas of poorly differentiated sarcoma (Supplementary 
Figure S5) in keeping with the diagnostic criteria for DDLPS.  Further, FISH analysis performed on the 
diagnostic tissue sample for MDM2 copy number (data not shown) was concordant with the array 
CGH results. It is therefore likely that this tumour belongs in this category of DDLPS with as yet 
undetermined specific genomic aberration. 
Given their range of subtypes, clinical, genomic and in vitro cultural features, the primary cell lines in 
this study are potentially much-needed additions to the number of cell lines of STS with complex 
genomics available that could comprise a drug testing panel akin to the NCI-60 panel that includes 
only more-prevalent cancers (Shoemaker, 2006; Taylor et al, 2011).  Further, a radio-resistant STS 
cell line may be utilised for the study of tumour response to radiation either alone or in combination 
with sensitising agents, as demonstrated was demonstrated with PARP inhibitors in Ewings’ sarcoma 
cell lines. (Garnett et al, 2012).   
The results of primary tissue culture in this study show the potential for establishment of short- and 
long term cell cultures from STS tissue.   The need for validation studies in short term cultures 
coupled with their finite nature and limited supply is however a practical limitation to their use by the 
wider research community.  All the long term cell lines in this study demonstrate genomic and 
phenotypic features that not only confirm their malignant characteristics, but also confirm the retention 
of the majority of SCNA present in their parent tumours that likely include ‘driver’ aberrations.    When 
combined with their rapid proliferation and abundance, they therefore represent an excellent model in 
vitro validation of genomic and transcriptomic targets in STS.   
Further, the establishment of separate clones that have been genetically confirmed as belonging to 
the same tumour in two cases will permit the evaluation of differential responses to therapeutic 
agents.  The combination of cryopreservation of early passages of these characterised cell lines as 
well as the potential to develop prospective short term cultures from other tumours of the same STS 
subtypes will serve to mitigate some of the concerns that have been raised with existing commercially 
available cell lines..  For further information on the availability of these cell lines, interested 
researchers should please contact the corresponding author. 
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Titles and Legends to Figures 
Figure 1:  Representative Phase contrast micrographs of STS primary cell lines A: Shef-UPS 01 – spindle 
shaped cells at passage 69 without distinct colony formation in culture.  B: Shef-UPS 03 cultures at passage 35 
showing homogenous cultures of long spindle-shaped cells growing in loose colonies. C: Shef-DDLPS 01 
cultures at passage 71 showing pleomorphic cells without distinct colony formation.  D:  Shef-DDLPS 02 cultures 
at passage 22 composed of a combination of spindle-shaped cells (white arrows) and round, histiocyte-like cells 
(black arrows), both growing in distinct colonies.   E and F:  Cells derived from Shef-LMS 01 growing in separate 
cultures designated Ws (passage 69) and w1 (passage 56), respectively. G and H:  Morphologically distinct cells 
derived from Shef-MFS 01 growing in separate adherent cultures designated w1 (passage 35) and w2 (passage 
31) respectively.  Scale bars = 100µm 
UPS – Undifferentiated Pleomorphic Sarcoma, DDLPS – Dedifferentiated Liposarcoma, LMS – Leiomyosarcoma, 
MFS - Myxofibrosarcoma 
 
Figure 2:  Genomic Copy Number Profile Comparisons of Seven Soft Tissue Sarcoma (STS) Primary 
Cell lines (shown on the left) with their parent tumours.   
Individual cell lines, STS subtype and passage number at which genomic DNA was extracted are shown to the 
left of the corresponding autosome ideograms.  The overlaid red and blue lines represent the moving average of 
log2 ratios of the cultured cells and parent tumour tissue, respectively.  Deviations above and below the horizontal 
baseline represent amplifications and deletions, respectively.  Relative amplitude of deviation shows the log2 ratio 
and represents DNA copy number at the corresponding genomic locus.  Note the close similarity and/or near-
identical breakpoints in the moving average patterns in each case over the majority of the genome.   
Copy number analysis was performed on the Agilent® 4 x 180K DNA microarray platform and data analysed 
using Agilent ® Genomic Workbench Software v6.0 
 
Figure 3: Selected Chromosome Copy Number Profile Comparisons of Soft Tissue Sarcoma (STS) 
Primary Cell lines with their parent tumours.   
Ideograms of specific chromosomes are as shown at the top of each panel with the corresponding regions at the bottom. The 
overlaid red and blue lines represent the moving average of log2 ratios (vs normal genomic DNA) of the cultured cells and 
parent tumour tissue, respectively.  Deviations above and below the horizontal baseline represent amplifications and deletions, 
respectively.  Amplitude of deviation shows the relative log2ratio and represents relative DNA copy number.  Note the close 
similarity and/or near-identical breakpoints in the moving average patterns in each case.   
Copy number analysis was performed on the Agilent
®
 4 x 180K DNA microarray platform and data analysed using Agilent
 ®
 
Genomic Workbench Software v6.0 



1STS Subtype Obtained
Not Established in 
Culture Early Senescence
Senescent around 
p5
Senescent around 
p10 Long Term Culture
Alveolar Soft Part Sarcoma 2 - - 1 1 -
Angiosarcoma 6 - 3‡ 2 1 -
Dedifferentiated Liposarcoma 7 3 2 - - 2*
Ewing’s Sarcoma 1 - - - 1* -
Extraskeletal Myxoid Chondrosarcoma 1 - - 1 - -
Leiomyosarcoma 3 1 - - 1 1
Low grade Myofibroblastic Sarcoma 1 - - 1 - -
Malignant Peripheral Nerve Sheath Tumour 1 - - 1 - -
Malignant Solitary Fibrous Tumour 1 - - 1 - -
Myxofibrosarcoma 5 - 3 - 1 1
Myxoid Liposarcoma 1 1 - - - -
Pleomorphic Liposarcoma 2 1* - 1‡ - -
Pleomorphic Rhabdomyosarcoma 1 - - - 1* -
Synovial Sarcoma 1 - - 1 - -
Undifferentiated Pleomorphic Sarcoma 7 2** 1 - 1 3
Well-differentiated Liposarcoma 7 6§ 1 - - -
Total 47 14 10 9 7 7
Number of Cases
‡ - One case was a metastatic tumour
Table 1:  A Summary of Fresh Soft Tissue Sarcoma Subtypes obtained and their Primary Cell Culture Outcomes.
§  - Three cases were recurrent tumours
** - Both cases received neo-adjuvant radiotherapy or chemotherapy
* - One case received neo-adjuvant radiotherapy or chemotherapy
Cell Line Laboratory Designation Morphology
Doubling Time* 
(hrs) Age/Gender STS Subtype Site Size
TNM    
Stage Immunocytochemistry
STS 02/11
STS 21/11
Upper Limb
Shef-UPS  01 53y/F
Mostly spindle shaped cells                                  
Some pleomorphism                                             
No distinct colony formation
Vimentin - positive
CK, SMA, cKit -  negative
STS 09/10
p70 = 40.55 Vimentin - positive
CK, SMA, cKit -  negative
300mm
Leiomyosarcoma
Lower Limbp35 = 63.97
Shef-UPS  02 76y/M
w1 
Spindle shaped cells with distinct nuclei
No pleomorphism
No distinct colony formation
Lower Limb 230mm
Table 2:  Characteristics of Primary Soft Tissue Sarcoma Cell Lines and their Parent Tumours
Vimentin, SMA - positive
CK, cKit -  negative
STS 14/10
2 distinct cell types in same culture
A – long spindle shaped cells 
B – rounded, histiocyte-like cells with distinct 
nuclei
STS 06/11
STS 09/11
Pleomorphic                                                          
mostly spindle shaped cells
No distinct colony formation
Pelvis
Long spindle shaped cells
No pleomorphism
Loose colony formation
pT2b    
Stage III
62y/F
Retroperitoneum
Undifferentiated 
pleomorphic 
sarcoma
Undifferentiated 
pleomorphic 
sarcoma
Vimentin - positive
CK, SMA, cKit -  negative
170mm
73y/M
ypT2b   
Stage III
Myxofibrosarcom
a
Vimentin - positive
CK, SMA, cKit -  negative
115mm
pT2b     
Stage III
135mm
Vimentin - positive
CK, SMA, cKit -  negative
50mm
170mmLower Limb
70y/F
Undifferentiated 
pleomorphic 
sarcoma
66y/F
p91 = 35.38
Shef-LMS  01
STS 20/11
pT2b    
Stage III
w1p35 = 59.93
Lower Limb
long spindle-shaped cells
No pleomorphism
Tight colony formation
68y/F
w1p54 = 27.44
pT1b    
Stage IIA
pT2b    
Stage III
pT1b    
Stage IIA
Shef-UPS  03
w1 
rounded, histiocyte-like cells with distinct nuclei
No pleomorphism
Tight colony formation
p23 = 58.22
* - passage number at which proliferation assay was performed is indicated
w1 – rounded, histiocyte-like cells
No pleomorphism
Tight colony formation
wsp63 = 44.62
De-differentiated 
Liposarcoma
De-differentiated 
Liposarcoma
w2p35 = 49.5
CK = cytokeratin, SMA = Smooth muscle Actin, cKit = CD117
w2 
w2 – polygonal cells
No pleomorphism
Loose colony formation
§ - patient received neoadjuvant radiotherapy
w2p31 = 56.30
§Shef-DDLPS  02
Shef-DDLPS  01
Shef-MFS  01
Vimentin, SMA - positive
CK, cKit -  negative
ws 
1
THO1 D21S11 D5S818 D13S317 D7S820 D16S539 CSFIPO AMEL vWA TPOX
p31 6,7 27,30 12,13 8,11 8 14 12 X 16 8
p68 6,7 27,30 12,13 8,11 8 13,14 12 X 16 8
p41 6,9.3 29,31 9,13 14 8,11 11 10,11 X, Y 17,18 8
p83 6,9.3 29,31 9,13 14 8,11 11 10,11 X 17,18 8
P34 9.3 28,31.2 9,12 11 10 9 10 X 17 8
w2p35 6 29,32 12,13 8,14 9,10 9,10 10,14 X 17,18 11
w2P70 6 29,32 12,13 8,14 9, 10 9,10 10,14 X 17,18 11
p2 9 29 9 14 10,12 12 12 X 20 9,11
w1p16 9 27,30 11 14 10,11 11 10,12 X 16 8
w1p54 9 27,30 11 14 10,11 11 10 X 16 8
wsp27 9 27,30 11 14 10,11 11 10,12 X 16 8
wsp63 9 27,30 11 14 10,11 11 10,12 X 16 8
w1p35 8 30,31.2 12,13 13 8,9 12 10 X, Y 14,16 11
w2p31 8 30,31,2 12,13 13 8,9 12 10 X, Y 14,16 11
Table 3:  Short Tandem Repeat (STR) Profiles of Primary STS Cultures
Profiles comprise the alleles at 10 STR loci.  No significant match (>80% relatedness) was found when compared to profiles in the COGcell database (http://strdb.cogcell.org/).    
Profiles for morphologically distinct variants derived from two STS cases (shown in bold) are identical
Cell Line/Passage
*Shef-DDLPS  01
*Shef-UPS  01
* - STR profiling repeated after one year (30-40 subsequent passages) and disparities in allele matching is highlighted in grey 
*Shef-UPS  02
Shef-DDLPS  02
Shef-MFS  01
*Shef-LMS  01 
Shef-UPS  03
1
